Dr. Sardesai stated in his presentation, Achieving positive data from the important ferret model is a vital addition to the positive mice and swine data we already reported for our H1N1 SynCon?„? DNA vaccine candidates. Together with our previously published H5N1 avian flu virus data, which highlighted the vaccine ™s cross-reactivity and broad immunogenicity across unmatched strains and included protection data in mice, ferrets, and non-human primates, these new H1N1 results further demonstrate the potential to protect against new strains of influenza that do not specifically match the vaccine “ unlike conventional vaccines, which are strain-specific and usually provide limited protection against emerging, divergent strains of influenza.

Dr. J. Joseph Kim, Inovio ™s CEO, said, This is another important step on our development path toward a universal influenza vaccine, which is intended to be a proactive rather than reactive approach to addressing both seasonal and pandemic strains. The beauty of our approach is that we can design universal DNA vaccines with broad protective capabilities against known and unknown strains. Our H1N1 vaccine candidates have achieved the desired outcomes in several relevant animal models against multiple unmatched virus strains. We are advancing our program with H1N1 as well as for the H2, H3 and H5 sub-types that would also be components of a universal vaccine. To this end, we have initiated cGMP clinical product manufacturing of our H1N1 SynCon?„? vaccine candidate.

Source: Inovio Biomedical Corporation